In this episode of Regulatory: The Emerging C-Suite Leader podcast, our hosts Debra Webster and Trevor Mill sit down with Murray Abramson, Chief Development Officer at Ascidian, to explore what it takes to accelerate drug development in complex settings, particularly in diseases with limited patient populations.
Acceleration is often misunderstood. It is not about speed alone. Without a foundation in data, patient insight, and regulatory alignment, timelines are built on hope rather than reality.
The discussion highlights the importance of early, integrated planning across clinical, regulatory, and CMC functions. Misalignment across these areas is one of the most common reasons accelerated programs fall short, particularly when protocols are built in isolation or timelines are set without grounding in prior experience. Adaptive trial designs can create efficiencies, but they are not a universal solution and must be applied in the context of the disease, modality, endpoints, and available biomarkers.
Identifying and continuously reassessing the “source of truth” is critical, meaning grounding decisions in data rather than assumptions. This includes patient needs, enrollment feasibility, regulatory expectations, and operational realities. Successful programs are those that address risks early, create an environment where challenges are surfaced before they become crises, maintain open communication across teams and with regulators, and adapt as new information emerges.
A clear tension exists between urgency and rigor. There is a moral imperative to move quickly for patients, but only when speed is supported by scientific rigor, transparency, and a well-grounded development strategy.
Hear it in Murray's own words.
What is Regulatory: The Emerging C-Suite Leader?
Welcome to Regulatory: The Emerging C-Suite Leader — the podcast where regulatory isn’t just a checklist. It’s leadership.
Hosted by Debra Aub Webster and Trevor Mill — two of our Chief Regulatory Officers — this show goes behind the scenes of biotech’s highest-stakes decisions. From FDA meetings that define the future of a company to global strategies that set the pace for clinical success, we explore how regulatory thinking becomes strategic advantage.
Each episode features candid conversations with seasoned leaders who’ve navigated accelerated programs, first-in-human trials, and critical inflection points. These are the lessons you won’t find in a training deck.
If you're a biotech executive, investor, or regulatory leader, this podcast is for you.
Because regulatory affairs isn’t just about approval — it’s about direction.